Adults with lifelong or very severe hearing or visual impairment: health, well-being and social careStatus:Awaiting developmentExpected publication date: TBC
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Deucravacitinib for treating active Sjogren's disease [ID6715]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [GID-TA12010]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MK-3000 for treating diabetic macular oedemaStatus:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 11 November 2026
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Satralizumab for treating thyroid eye disease [ID6648]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Timrepigene emparvovec for treating choroideremia [ID3916]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Veligrotug for treating thyroid eye disease [ID6636]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vonaprument for treating geographic atrophy caused by age-related macular degenerationStatus:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC